Dexcom, Inc., San Diego, California, USA.
Kelly Statistical Consulting, Carlsbad, California, USA.
Diabet Med. 2022 Feb;39(2):e14739. doi: 10.1111/dme.14739. Epub 2021 Nov 23.
Prior to the Continuous Monitoring and Control of Hypoglycaemia (COACH) study described herein, no study had been powered to evaluate the impact of non-adjunctive RT-CGM use on the rate of debilitating moderate or severe hypoglycaemic events.
In this 12-month observational study, adults with insulin-requiring diabetes who were new to RT-CGM participated in a 6-month control phase where insulin dosing decisions were based on self monitoring of blood glucose values, followed by a 6-month phase where decisions were based on RT-CGM data (i.e. non-adjunctive RT-CGM use); recommendations for RT-CGM use were made according to sites' usual care. The primary outcome was change in debilitating moderate (requiring second-party assistance) and severe (resulting in seizures or loss of consciousness) hypoglycaemic event frequency. Secondary outcomes included changes in HbA1c and diabetic ketoacidosis (DKA) frequency.
A total of 519 participants with mean (SD) age 50.3 (16.1) years and baseline HbA1c 8.0% (1.4%) completed the study, of whom 32.8% had impaired hypoglycaemia awareness and 33.5% had type 2 diabetes (T2D). The mean (SE) per-patient frequency of hypoglycaemic events decreased by 63% from 0.08 (0.016) during the SMBG phase to 0.03 (0.010) during the RT-CGM phase (p = 0.005). HbA1c decreased during the RT-CGM phase both for participants with type 1 diabetes (T1D) and T2D and there was a trend towards larger reductions among individuals with higher baseline HbA1c.
Among adults with insulin-requiring diabetes, non-adjunctive use of RT-CGM data is safe, resulting in significantly fewer debilitating hypoglycaemic events than management using SMBG.
在本文所述的持续监测和低血糖控制(COACH)研究之前,尚无研究能够评估非辅助性实时连续血糖监测(RT-CGM)使用对衰弱性中度或重度低血糖事件发生率的影响。
在这项为期 12 个月的观察性研究中,新使用 RT-CGM 的需要胰岛素治疗的糖尿病成人患者参与了为期 6 个月的对照阶段,在此阶段,胰岛素剂量决策基于自我监测的血糖值,随后进入为期 6 个月的阶段,在此阶段,决策基于 RT-CGM 数据(即非辅助性 RT-CGM 使用);根据各站点的常规护理提出 RT-CGM 使用建议。主要结局是衰弱性中度(需要第三方协助)和重度(导致癫痫发作或失去意识)低血糖事件频率的变化。次要结局包括 HbA1c 和糖尿病酮症酸中毒(DKA)频率的变化。
共有 519 名平均(标准差)年龄 50.3(16.1)岁且基线 HbA1c 为 8.0%(1.4%)的患者完成了研究,其中 32.8%存在低血糖感知受损,33.5%患有 2 型糖尿病(T2D)。与 SMBG 阶段的 0.08(0.016)相比,RT-CGM 阶段每位患者低血糖事件的平均(SE)频率降低了 63%,降至 0.03(0.010)(p=0.005)。在 RT-CGM 阶段,1 型糖尿病(T1D)和 T2D 患者的 HbA1c 均下降,且基线 HbA1c 较高的个体中 HbA1c 降低的趋势更大。
在需要胰岛素治疗的糖尿病成人中,非辅助性 RT-CGM 数据的使用是安全的,与使用 SMBG 相比,显著减少了衰弱性低血糖事件的发生。